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Arterial hypertension (HT) is age dependent and, with the prolongation of life expectancy, aﬀects more and more elderly people.
In the elderly, HT is a risk factor for organ damage and cardiovascular (CV) events. Both pharmacologic and nonpharmacologic
reduction of blood pressure (BP) is associated with a corresponding decrease in systolic-diastolic or isolated systolic HT. Clinical
trials have shown that BP lowering is associated with a decrease in stroke and other CV events. Therefore, BP reduction per se
appears more important than a particular class of antihypertensive drugs. The beneﬁt of antihypertensive treatment has been
conﬁrmed up to the age of 80 years, remaining unclear in the octogenarians. The beneﬁt in lowering diastolic BP between 80 and
90mmHg is well established, while that of lowering systolic BP below 140mmHg requires further conﬁrmations.
The lifespan increase during the last 30 years has resulted in
a remarkable raise in the world population of people aged
≥65 years [1]. Arterial hypertension (HT) is age dependent
and, with the prolongation of life expectancy, aﬀects more
and more elderly people [2]. Approximately over 80% of
the elderly have HT, mainly isolated systolic hypertension
(ISH), deﬁned in the European guidelines as systolic blood
pressure(BP) ≥140mmHganddiastolicBP<90mmHg[3].
ISH is an age-related condition, as systolic BP increases with
advancing age, while diastolic remains unchanged or even
decreases after the sixth decade of life [4]. This phenomenon
produces a progressive increase in pulse pressure (PP) [5].
PP, the diﬀerence between systolic and diastolic BP, reﬂects
the work increase due to systolic energy [6, 7].
In clinical practice, the decision to treat an elderly with
HT depends on the answers to the following three questions
(i) Is HT a risk factor for stroke and cardiovascular (CV)
events?
(ii) Does non-pharmacologic and pharmacologic treat-
ment reduce the risk of these events?
(iii) Which is the target to achieve in the elderly hyperten-
sives?
The aim of this paper is to answer these questions,
particularlyfocusingthediscussiononwhethertheparadigm
“the lower, the better” maintains a prognostic role in elderly
and very old hypertensives.
In clinical trials completed before 1985, elderly hyper-
tensive subjects were not included or represented a little
component of the population under investigation [8]. At
the beginning of the 90s, when the ﬁrst epidemiological
evidences documented the prognostic role of systolic BP
[9, 10], many trials were performed in elderly hypertensives
(Table 1). On the basis of the evidence provided by these
trials, HT is now considered a well-established risk factor for
stroke and CV disease in elderly people, and its treatment is
considered as mandatory.2 International Journal of Hypertension
Table 1: Eﬃcacy of the antihypertensive treatment in stroke and cardiovascular events in diﬀerent trials performed in the elderly.
Trial
Mean age at
randomization
(years)
Subjects
enrolled
Mean BP at
randomization
(mmHg)
Drug treatment Mean followup
(years)
Stroke
Reduction (%)
CV events
reduction (%)
SBP DBP
Coope/Warrender 68 884 196 99 Atenolol;
Bendroﬂuazide 4,04 −30 —
EWPHE 72 840 183 101
HCTZ;
Triamterene;
Methyldopa
8N S −27
HYVET 84 3845 173 91 Indapamide;
Perindopril 2 −30 −34
MRC-HT 70 4396 185 91
Atenolol;
HCTZ;
Amiloride
5,8 −31 −35
SHEP 72 4716 170 77 Chlorthalidone 4,5 −36 −32
STONE 67 1632 180 90 Nifedipine
(Long-acting) 2,5 −57 −60
STOP-HTN 76 1627 195 94
Atenolol;
HCTZ;
Amiloride;
Metoprolol;
Pindolol
5 −47 −40
Syst-China 67 3000 171 86
Nitrendipine;
Captopril;
HCTZ
2 −38 −37
Syst-Eur 70 4695 174 85
Nitrendipine;
Enalapril;
HCTZ
2 −42 −31
SBP: systolic blood pressure; DBP: diastolic blood pressure; EWPHE: European Working Party on High blood pressure in the Elderly trial; HYVET:
hypertension in the very elderly; MCR: Medical Research Council Hypertension Trial; SHEP: systolic hypertension in the elderly; STONE: Shanghai Trial of
Hypertension in the Elderly; STOP-HTN: Swedish Trial in Old Patients with Hypertension; Syst-China: systolic hypertension in China; Syst-Eur: Systolic
Hypertension in Europe; NS: not signiﬁcant; HTCZ: hydrochlorothiazide.
In the elderly hypertensives, antihypertensive treatment
is commonly recommended, but with high caution due to
alterations in drug distribution and disposal, to presumptive
changes in homeostatic CV control and to the quality of life
that is typical of this age class. The randomized, controlled
trialsofantihypertensivetreatmentintheelderlyhaveshown
beneﬁts comparable to those observed in younger or middle-
aged subjects. Not only this, but, as the baseline CV risk
is higher in the elderly, the absolute beneﬁt of treatment
(expressed as number of events prevented per 1000patient-
years) is even higher in the elderly. However, most of the
hypertensives enrolled in clinical trials were <80 years old.
The ﬁrst evidence that antihypertensive treatment is also
useful in subjects aged ≥80 years is that published in 1999
by Gueyﬃer et al., concerning a subgroup of 1,670 very
old subjects taking part of the INdividual Data ANAlysis of
antihypertensive intervention trials (INDANA) [11]. In this
meta-analysis, antihypertensive therapy led to a reduction
in stroke (−33%), CV morbidity (−22%), and heart failure
(−39%).Nosigniﬁcanteﬀectwasdemonstratedforcoronary
events,andwhentheeﬀectoftreatmentonfatalandnonfatal
stroke was analyzed separately the beneﬁt was limited to the
nonfatal only. Ten years later, similar results were partially
conﬁrmed in the Hypertension in the Very Elderly Trial
(HYVET) over 3,845 subjects aged ≥80 years and having
high systolic BP [12], where all subjects were randomly
assigned to placebo or active treatment with indapamide
and perindopril was added in individuals who failed to meet
the target BP of 150/80mmHg. At two years of followup,
mean BP was 15/6mmHg lower in subjects receiving active
treatment than in those receiving the placebo, a diﬀerence
that was associated with signiﬁcant reduction of death from
stroke, both fatal and non-fatal (−30%), cardiovascular
disease (−23%), and heart failure (−64%).
In the HYVET, a 21% reduction of the risk of overall
mortality was also observed with active treatment. Nev-
ertheless, the results of Bejan-Angoulvant’s meta-analysis
did not support those of the HYVET, showing comparable
overall mortality in treated and untreated patients [13]. This
discrepancy was outlined in the recent joint consensus devel-
opedbytheAmericanCollegeofCardiologyFoundationand
the American Heart Association [14]. The subjects enrolled
in the HYVET were in good physical and mental condition
and had low rate of previous CVD and therefore were not
representative of very elderly.
Systolic HT (≥140mmHg) and pulse HT (≥80mmHg) [6]
characterise the pressure proﬁle of elderly hypertensives. It
is therefore only natural that the intervention trials wereInternational Journal of Hypertension 3
focused on reducing systolic BP. The current ESH/ESC
guidelines recommend reducing systolic BP below
140mmHg in grade 1-2 hypertensives having low-
to-moderate total CV risk. Nevertheless, whether this
recommendation also applies to elderly and very old
s u b j e c t si su n p r o v e db yo u t c o m et r i a l s .I na l lt r i a l s[ 15–22]
but one [23], elderly hypertensives randomized to more
active treatment had lower incidence of CV events, but
in no trial the systolic target (<140mmHg) was reached.
The ACCOMPLISH [24] and the INVEST [25] studies
showed no diﬀerence in antihypertensive eﬀects when
comparing drug treatment in subjects of age ≥80 or <80
years, implicitly supporting the opportunity to treat very
old subjects. Nevertheless, the Japanese Trial to Assess
Optimal Systolic (JATOS) blood pressure in elderly hyper-
tensive patients over-65–85-year-old subjects, (JATOS)
demonstrated that a more strict BP control did not provide
further beneﬁt in reducing stroke, heart disease, vascular
disease, and renal failure [23] and even showed a negative
result on CV events suggesting a possible deleterious eﬀect
of intensive BP control in elderly hypertensives. This is
not peculiar of old subjects, being in agreement with the
results of the ACCORD trial [26] that showed no additional
beneﬁt of BP reduction—but only an increase in drug-
related adverse eﬀects in—high-risk patients with diabetes
mellitus ≥55 years when targeting systolic at 120 rather than
140mmHg. In addition, observational data from INVEST in
hypertensive patients with coronary artery disease showed
a J-curve pattern for adverse outcomes at on-treatment
systolic BP of 135mmHg in patients aged 70 to 79 years
and at 140mmHg for those aged ≥80 years. This is not a
new notation, as some retrospective analyses of intervention
studies suggested [27]w i t he x c e p t i o n s[ 17–22]aJ - c u r v e
trend of the risk of myocardial infarction in relation to
treated BP. Also in a posthoc analysis of the EWPHE [15]i t
appears that in elderly hypertensives under active treatment
total mortality had a U-shaped trend in relation to systolic
BP, with a nadir about 150mmHg, whereas total mortality
increased gradually with decreasing DBP from the upper
tertile of 98mmHg (these results were partially ﬂawed by
the fact that a U-shaped trend with a nadir at 95mmHg was
also found in the patients taking placebo, so that conclusive
inferences cannot be drawn from this retrospective analysis).
Finally, in the Hypertension Optimal Treatment (HOT)
study [28], where 30% of the hypertensives were older than
65 years, it was found that the optimal BP for the lowest
incidence of CV events was 138 mmHg for systolic and
83mmHg for diastolic, with no signiﬁcant improvement
in CV end-points when BP was led to lower levels. The
intention-to-treat analysis revealed a comparable pattern in
the incidence of CV events in the adults and in the older
patients, suggesting that optimal BP reductions are similar
and independent of age.
Therefore, no trial evidence supports the guidelines
recommendation to achieve a systolic target <140mmHg in
elderly subjects; in particular systolic values <130 and di-
astolic <65mmHg should probably be avoided in the elderly.
In conclusion, particular attention should be paid to
antihypertensive treatment of elderly hypertensives, which
constitute a large, growing, and vulnerable part of gen-
eral population. There is no doubt that antihypertensive
treatment is justiﬁed by medical evidence. The assumption
“the lower systolic BP, the lower the risk” is adequate
for stroke and heart failure. Despite this, the best meta-
analysis showed no clear results in decreasing total mortality
by forcing antihypertensive treatment in very old subjects.
In the randomized-controlled trials, elderly hypertensives
were treated with diuretics, β-blockers, dihydropyridines
calciumchannelblockers,andconverting-enzymeinhibitors.
However, monotherapy normalizes BP in only 40–50% of
cases, and therefore a combination of two or more drugs
is often required to achieve the recommended BP goals.
The most reasonable strategy is to start with a thiazide
diuretic as ﬁrst-line therapy and to optimize the maximal
antihypertensive therapy with two drugs in low doses. The
JNC, the WHO/ISH, and ESH/ESC guidelines recommend
lowering BP in elderly hypertensives below 140/90mmHg.
In this respect there are suﬃcient data that a diastolic
BP between 80 and 90mmHg is associated with a clear
beneﬁt, except in case of coronary heart disease where a
mortality increase was observed reducing diastolic BP below
80mmHg.
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